Atom Investors LP Cogent Biosciences, Inc. Transaction History

Atom Investors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.01 - $9.04 $104,021 - $156,464	-17,308 Reduced 42.75%	23,174 $195,000
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $274,774 - $565,860	-62,734 Reduced 60.78%	40,482 $272,000
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $267,221 - $663,445	65,818 Added 175.99%	103,216 $606,000
Q3 2023 Nov 14, 2023	BUY	$9.69 - $13.34 $233,567 - $321,547	24,104 Added 181.31%	37,398 $364,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.24 $99,997 - $134,412	-10,152 Reduced 43.3%	13,294 $157,000
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $611,415 - $943,919	-60,898 Reduced 72.2%	23,446 $252,000
Q4 2022 Feb 14, 2023	BUY	$10.65 - $14.84 $504,618 - $703,148	47,382 Added 128.19%	84,344 $975,000
Q3 2022 Nov 08, 2022	SELL	$9.39 - $16.99 $401,882 - $727,155	-42,799 Reduced 53.66%	36,962 $551,000
Q2 2022 Aug 15, 2022	SELL	$3.92 - $9.73 $139,814 - $347,039	-35,667 Reduced 30.9%	79,761 $719,000
Q1 2022 May 16, 2022	BUY	$5.31 - $8.7 $287,101 - $470,391	54,068 Added 88.12%	115,428 $865,000
Q4 2021 Feb 14, 2022	BUY	$7.51 - $10.81 $460,813 - $663,301	61,360 New	61,360 $526,000

173

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $549M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.